You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Testing a male oral contraceptive targeting Eppin

    SBC: EPPIN PHARMA INC            Topic: NICHD

    The global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryOver $billion is spent annually in the US treating chronicnon healing woundsmany of which face lifethreatening complications due to infectionsWound infections are difficult to treat due to the frequency of antibiotic resistance as well as the formation of biofilmsa community of bacteria covered by an extracellular polymeric substanceBiofilm related infections can result in a substan ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Innovative TME-specific Pro-CAR T-cells for Immunotherapy of Solid Tumors

    SBC: Panacise Bio, Inc.            Topic: 102

    Abstract This project seeks to develop the next generation pro CARs that are inactive in normal tissues but selectively activated in the tumor microenvironmentTMEThe project is based on our previous development of a novel class of chimeric antigen receptors on the basis of single domain antibody mimics that recognize ErbB family membersSDAErbBon the surface of cancer cellsWe propose two specific a ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Quantifying NETosis via Automated High Content Imaging Convolutional Neural Networks

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARY NETosis was identified as a distinct mode of cell death in neutrophils more than a decade agoDysregulation of NETosis has been implicated in the etiology of human pathologies such as preeclampsiasickle cell diseasesystemic lupus erythematosusmultiple sclerosisrheumatoid arthritissepsiscystic fibrosislupus nephritisand coagulopathies that include cancer associated thrombosisThe lite ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Reprogrammed T Cells to prevent graft versus host disease

    SBC: Element Genomics, Inc.            Topic: NIAID

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to develop an efficient and robust method to epigenetically reprogram na ve human T cells into regulatory T cellsTregsthat can prevent graft versus host diseaseGvHDOur short term goal for Phase I of the STTR award is to demonstrate that we can epigenetically reprogram na ve T cells using CRISPR Casbased technology into immunosuppressive ce ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A cell-free, high-throughput screening service for accelerated GPCR ligand discovery

    SBC: KXT BIO INC.            Topic: 300

    PROJECT SUMMARY The proposed Phase I STTR project is a partnership between a biotechnology company KXTbioIncand the University of North Carolina at Chapel Hill to develop an innovative high throughput screening service for identifying new drug candidates that act via G protein coupled receptorsGPCRsThis large protein superfamily has been the most successful source of therapeutic targetsaccounting ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA

    SBC: COLLABORATIONS PHARMACEUTICALS INC            Topic: NIAID

    Project Summary The continued spread of drug resistant Mycobacterium tuberculosisMtbinfections has rendered tuberculosisTBa global health pandemic and pressed home the urgent need for new drugsCompounds which inhibit essential components of the Mtb cell wall rapidly cause cell death and are represented clinically by isoniazidIf any drug combination is likely to reduce treatment duration and preven ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infectionsBSIscaused by Gram negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic resistant nature of the pathogensInfections caused by multi drug resistantMDRbacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic optionsThis lack of treatment options is particularly relevant fo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government